23andMe Investor Presentation Deck

GENETICS 23andMe Therapeutics: Genetics Reimagining R&D Our Value Proposition Our credo: Every Day Matters Higher probability of success in the clinic Forward-thinking expert team • Current focus: Oncology Development, Immunology Discovery • Fast timelines and early kill decisions from discovery through clinical development to approval • Indication selection informed by lifetime genetic risk based on world's largest human genotypic & phenotypic data platform • Genetics (e.g. GWAS, PRS) and biomarkers to optimize target- indication-patient clusters • Experienced, innovative genetics researchers and clinical development team with track record for innovative approvals Genetics and clinical development scientists to identify higher success programs to bring into the clinic Copyright © 2024 23and Me, Inc. 23andMe 3

View entire presentation